Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13848500 | 0.91 | PTGS1 (0.40) | PTGS1GSTK1GLO1NOD1 | |
| SCHEMBL27587945 | 0.84 | MME (0.42) | TGFBR1MMENOD1 | |
| SCHEMBL4129529 | 0.84 | MME (0.42) | TGFBR1MMENOD1 | |
| SCHEMBL29592504 | 0.83 | PTGS1 (0.44) | PTGS1GSTK1GLO1MMEOPRD1 | |
| SCHEMBL30662551 | 0.83 | CA2 (0.47) | PTGS1GSTK1GLO1MMENOD1 | |
| SCHEMBL31479814 | 0.82 | PTGS1 (0.40) | PTGS1GSTK1GLO1MMEOPRD1 | |
| SCHEMBL30090437 | 0.82 | TGFBR1 (0.45) | PTGS1GSTK1GLO1TGFBR1MME | |
| SCHEMBL29579224 | 0.81 | PTGS1 (0.50) | PTGS1GSTK1GLO1 | |
| SCHEMBL22315777 | 0.81 | PTGS1 (0.50) | PTGS1GSTK1GLO1 | |
| SCHEMBL31544030 | 0.81 | ECE1 (0.39) | PTGS1GSTK1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027192-A1 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | UNIV HONG KONG SCIENCE & TECH (CN) | 2026-01-29 | — | — | US | disclosed |
| WO-2024141791-A2 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027192-A1 | COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT | IAPP, NPY1R, GLP1R | PTGS1 1868/4885GSTK1 1717/4885GLO1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.